Clinical trials have surpassed 1 million registrations globally since 2000, but only 15% of experimental drugs make it through clinical testing. The full path from Phase I to approval typically runs 6 to 7 years, so small delays compound across each study stage.
Key Takeaways
- Phase I trials take average 2.1 years to complete.
- Phase II trials average 2.5 years duration.
- Phase III trials last average 3.2 years.
- Protein degraders (PROTACs) pipeline: 100+ candidates.
- mRNA therapeutics market to $127 billion by 2030.
- Cell and gene therapy approvals doubled since 2017.
- AI drug discovery investments $20 billion in 2022.
- Global pharma market size was $1.48 trillion in 2022.
- US pharma market share 45% of global at $675 billion in 2022.
- Biologics market projected to $500 billion by 2025.
- The average cost to bring a new drug to market is approximately $2.6 billion, including failure rates.
- Global pharmaceutical R&D spending reached $238 billion in 2022.
- R&D expenditure by top 20 pharma companies was $162 billion in 2021.
- FDA approved 37 new drugs in 2022.
- EMA approved 39 new medicines in 2022.
Clinical development is slow and risky, with only 8.4% of Phase I drugs reaching approval over 6 to 7 years.
Related reading
01 · Category
Clinical Trials;,27 stats
01
Phase I trials take average 2.1 years to complete.
02
Phase II trials average 2.5 years duration.
03
Phase III trials last average 3.2 years.
04
Overall clinical trial timeline is 6-7 years from Phase I to approval.
05
85% of experimental drugs fail in clinical trials.
06
Phase I success rate to Phase II is 63%.
07
Phase II to Phase III success rate is 31%.
08
Phase III to approval success rate is 58%.
09
Over 1 million clinical trials registered globally since 2000.
10
US hosts 45% of global clinical trials.
11
Average Phase III trial enrolls 300-3000 patients.
12
Oncology trials have 3.4% success rate from Phase I to approval.
13
Infectious disease trials success rate 20.6%.
14
Number of Phase I starts increased 8% YoY in 2022.
15
Adaptive trial designs used in 20% of Phase II/III trials in 2022.
16
Patient recruitment takes 30% of total trial time.
17
Decentralized trials grew 5x since 2020.
18
AI used in 25% of trial design processes in 2023.
19
Average trial site activation time is 3-6 months.
20
70% of trials are multinational.
21
Rare disease trials enroll median 20 patients.
22
Diversity in trials: 75% White, 8% Black participants in US.
23
Cost of Phase III trial averages $20-50 million.
24
Real-world evidence used in 15% of trials post-2020.
25
Basket/umbrella trials increased 300% since 2015.
26
Pediatric trials represent 5% of total trials.
27
Vaccine trials success rate 33.4% Phase I to approval.
Interpretation
Clinical Trials;, Interpretation
The drug development pipeline is a grueling, decade-long gauntlet where most hopeful molecules meet their demise, yet the industry soldiers on with a mix of stubborn optimism, adaptive designs, and a dash of AI, all while trying to recruit more than just the usual suspects.
02 · Category
Innovation Trends1 stats
01
Protein degraders (PROTACs) pipeline: 100+ candidates.
Interpretation
Innovation Trends Interpretation
The Protein degrader pipeline is now overflowing with over 100 candidates, suggesting that while the science is elegantly complicated, the strategy is simply to throw a highly targeted kitchen sink at the problem until something sticks.
03 · Category
Innovation Trends;,13 stats
01
mRNA therapeutics market to $127 billion by 2030.
02
Cell and gene therapy approvals doubled since 2017.
03
AI drug discovery investments $20 billion in 2022.
04
CRISPR gene editing trials: 50+ active in 2023.
05
Precision medicine market $110 billion in 2022.
06
CAR-T therapies approved: 6 by FDA as of 2023.
07
Organoid models used in 15% of preclinical studies 2023.
08
Digital twins in trials piloted by 20 pharma companies.
09
RNA interference (RNAi) drugs approved: 5 since 2018.
10
Nanotechnology drug delivery systems in 10% new approvals.
11
Microbiome therapeutics trials: 200+ ongoing.
12
Quantum computing pilots for drug discovery by 5 big pharma.
13
Wearables data in trials increased 400% post-COVID.
Interpretation
Innovation Trends;, Interpretation
The pharmaceutical industry, now turbocharged by AI and CRISPR, is boldly reimagining medicine from the molecule up, promising a future where your car might be recalled but your cells get a precision upgrade.
More related reading
04 · Category
Market Economics;,20 stats
01
Global pharma market size was $1.48 trillion in 2022.
02
US pharma market share 45% of global at $675 billion in 2022.
03
Biologics market projected to $500 billion by 2025.
04
Oncology drugs generated $203 billion revenue in 2022.
05
Top 10 pharma companies revenue $400 billion in 2022.
06
Pfizer revenue $100.3 billion in 2022 driven by COVID vaccines.
07
Roche sales CHF 63.3 billion in 2022.
08
J&J pharma sales $52.1 billion in 2022.
09
Merck revenue $59.3 billion in 2022.
10
Novartis sales $45.4 billion in 2022.
11
AbbVie revenue $58.1 billion in 2022.
12
AstraZeneca sales $45.8 billion in 2022.
13
Sanofi revenue €43.4 billion in 2022.
14
GSK sales £29.3 billion in 2022.
15
Bristol Myers Squibb revenue $46.2 billion in 2022.
16
Eli Lilly sales $28.5 billion in 2022.
17
Gilead revenue $27.1 billion in 2022.
18
Amgen sales $26.3 billion in 2022.
19
Generics market $100 billion in US 2022.
20
Biosimilars market $20 billion globally in 2022.
Interpretation
Market Economics;, Interpretation
The pharmaceutical industry is a staggeringly large ecosystem where a single therapeutic area like oncology can be a Fortune 500 company unto itself, yet the scramble for the next blockbuster drug means even the giants live or die by a single scientific breakthrough.
05 · Category
R&D Costs;,30 stats
01
The average cost to bring a new drug to market is approximately $2.6 billion, including failure rates.
02
Global pharmaceutical R&D spending reached $238 billion in 2022.
03
R&D expenditure by top 20 pharma companies was $162 billion in 2021.
04
Probability of success from Phase I to approval is 8.4% for all drugs.
05
Cost per approved drug has risen to $1.3 billion out-of-pocket since 2010.
06
Biopharma R&D investment hit $147 billion in 2020.
07
Average R&D intensity (R&D/sales) for pharma is 19-20%.
08
US biopharma firms invested $102 billion in R&D in 2021.
09
Capitalized cost of a new drug development is $2,794 million.
10
R&D spending grew 5.5% annually from 2017-2022.
11
Pfizer's R&D spend was $11.4 billion in 2022.
12
Roche invested CHF 13.4 billion in R&D in 2022.
13
Novartis R&D budget was $10.7 billion in 2022.
14
Merck & Co. spent $12.2 billion on R&D in 2022.
15
J&J R&D expenditure was $14.9 billion in 2022.
16
AstraZeneca R&D spend reached $8.1 billion in 2022.
17
Sanofi invested €6.3 billion in R&D in 2022.
18
GSK R&D budget was £5.0 billion in 2022.
19
Bristol Myers Squibb spent $9.0 billion on R&D in 2022.
20
Eli Lilly R&D investment was $7.6 billion in 2022.
21
AbbVie R&D spend totaled $6.5 billion in 2022.
22
Gilead Sciences invested $5.0 billion in R&D in 2022.
23
Amgen R&D expenditure was $4.5 billion in 2022.
24
Biogen spent $3.0 billion on R&D in 2022.
25
Regeneron Pharmaceuticals R&D was $4.2 billion in 2022.
26
Moderna invested $4.9 billion in R&D in 2022.
27
BioNTech R&D spend was €2.0 billion in 2022.
28
Vertex Pharmaceuticals R&D was $2.4 billion in 2022.
29
Incyte Corporation invested $900 million in R&D 2022.
30
Exelixis R&D spend was $500 million in 2022.
Interpretation
R&D Costs;, Interpretation
The pharmaceutical industry operates a multi-billion-dollar casino where the house edge is a brutal 91.6%, but the jackpot for a winning ticket is measured in human lives.
06 · Category
Regulatory Approvals;,22 stats
01
FDA approved 37 new drugs in 2022.
02
EMA approved 39 new medicines in 2022.
03
Average FDA review time for standard drugs is 10 months.
04
Priority review shortens FDA time to 6 months.
05
55 novel drugs approved by FDA in 2021.
06
Breakthrough Therapy designation granted to 98 drugs since 2012.
07
Orphan Drug Designation for 600+ products annually.
08
Accelerated Approval pathway used for 70% oncology drugs.
09
FDA issued 50 complete response letters in 2022.
10
PMDA Japan approved 40 new drugs in 2022.
11
Health Canada approved 45 new drugs in 2022.
12
TGA Australia approved 30 innovative medicines in 2022.
13
20% of approvals via Real-Time Oncology Review in 2022.
14
RMAT designation for 50+ cell/gene therapies since 2017.
15
FDA warning letters to pharma firms: 15 in 2022.
16
Post-approval changes require prior approval for 40% of submissions.
17
EU conditional marketing authorization for 10 drugs in 2022.
18
Fast Track designation for 150+ programs annually.
19
ANDA approvals: 700+ generics by FDA in 2022.
20
Biosimilar approvals reached 40 by FDA as of 2023.
21
Global harmonization via ICH guidelines adopted by 7 regions.
22
FDA user fee for NDA is $3.1 million in FY2023.
Interpretation
Regulatory Approvals;, Interpretation
The regulatory engines are clearly running hot, approving a steady stream of new treatments through a complex maze of expedited pathways, but the high costs, frequent rejections, and tight post-approval reins remind us that this medical marathon is run on a track paved with both gold and caution.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Aisha Okonkwo. (2026, February 13). Drug Development Industry Statistics. Gitnux. https://gitnux.org/drug-development-industry-statistics
MLA
Aisha Okonkwo. "Drug Development Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/drug-development-industry-statistics.
Chicago
Aisha Okonkwo. 2026. "Drug Development Industry Statistics." Gitnux. https://gitnux.org/drug-development-industry-statistics.
Sources & references
57 datasets cited across this report